Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis

Transplantation

Volumn 75, Issue 9, 2003, Pages 1581-1590

  Koenen, Hans J P M ^a   Michielsen, Etienne C H J ^a   Verstappen, Jochem ^a   Fasse, Esther ^a   Joosten, Irma ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; CYCLOPHILIN A; CYCLOSPORIN A; RAPAMYCIN; TACROLIMUS;

ALLOGENEIC RESTRICTION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; IMMUNOSUPPRESSIVE TREATMENT; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

APOPTOSIS; CALCINEURIN; CYCLOSPORINE; DNA-BINDING PROTEINS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIROLIMUS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS; TRANSCRIPTION FACTORS;

EID: 0037910271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000053752.87383.67     Document Type: Article

References (42)

1. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000; 12: 359.
2. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136.
3. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335.
4. Bierer BE, Hollander G, Fruman D, et al. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5: 763.
5. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483.
6. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.
7. Li XC, Li Y, Dodge I, et al. Induction of allograft tolerance in the absence of Fas-mediated apoptosis. J Immunol 1999; 163: 2500.
8. Shi YF, Sahai BM, Green DR. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 1989; 339: 625.
9. Yazdanbakhsh K, Choi JW, Li Y, et al. Cyclosporin A blocks apoptosis by inhibiting the DNA binding activity of the transcription factor Nur77. Proc Natl Acad Sci U S A 1995; 92: 437.
10. Linette GP, Li Y, Roth K, et al. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A 1996; 93: 9545.
11. Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 1990; 87: 9231.
12. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083.
13. Dumont FJ, Melino MR, Staruch MJ, et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
14. Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992; 176: 751.
15. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040.
16. Kahan BD, Gibbons S, Tejpal N, et al. Synergistic interactions ofcyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232.
17. Qi S, Xu D, Peng J, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 1275.
18. Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 1853.
19. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194.
20. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen [comments]. N Engl J Med 2000; 343: 230.
21. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression [letter]. Lancet 2000; 355: 376.
22. Koenen HJ, Joosten I. Blockade of CD86 and CD40 induces alloantigenspecific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood 2000; 95: 3153.
23. Li XC, Strom TB, Turka LA, et al. T cell death and transplantation tolerance. Immunity 2001; 14: 407.
24. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303.
25. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322.
26. Budd RC. Activation-induced cell death. Curr Opin Immunol 2001; 13: 356.
27. Adachi M, Sekiya M, Torigoe T, et al. Interleukin-2 (IL-2) upregulates BAG-1 gene expression through serine-rich region within IL-2 receptor beta c chain. Blood 1996; 88: 4118.
28. Shibasaki F, Kondo E, Akagi T, et al. Suppression of signaling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997; 386: 728.
29. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243.
30. Hu H, Huston G, Duso D, et al. CD4(+) T cell effectors can become memory cells with high efficiency and without further division. Nat Immunol 2001; 2: 705.
31. Bemer V, Motta I, Perret R, et al. Interleukin-2 down-modulates memory T helper lymphocyte development during antigenic stimulation in vitro. Eur J Immunol 1995; 25: 3394.
32. Gupta M, Satyaraj E, Durdik JM, et al. Differential regulation of T cell activation for primary versus secondary proliferative responses. J Immunol 1997; 158: 4113.
33. Farber DL. Differential TCR signaling and the generation of memory T cells. J Immunol 1998; 160: 535.
34. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998; 16: 201.
35. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272: 54.
36. + T cells to antigen stimulation in vivo. Nat Immunol 2000; 1: 47.
37. Kwon TK, Buchholz MA, Ponsalle P, et al. The regulation of p27Kip1 expression following the polyclonal activation of murine G0 T cells. J Immunol 1997; 158: 5642.
38. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570.
39. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162: 2775.
40. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349.
41. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165.
42. Ghobrial R, Karczewski M, Ferraresso M, et al. Kinetics of in vitro immune responses of T and B cells during tolerance induction by sirolimus. Ann Transplant 1996; 1: 22.